<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-2ISUPDXK</identifier><date>2001</date><creator>Čufer, Tanja</creator><relation>documents/doc/2/URN_NBN_SI_doc-2ISUPDXK_001.pdf</relation><relation>documents/doc/2/URN_NBN_SI_doc-2ISUPDXK_001.txt</relation><format format_type="issue">2</format><format format_type="volume">5</format><format format_type="type">article</format><format format_type="extent">str. 75-76</format><identifier identifier_type="ISSN">1408-1741</identifier><identifier identifier_type="COBISSID">14310617</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-2ISUPDXK</identifier><language>slv</language><publisher>Onkološki inštitut Ljubljana</publisher><source>Onkologija (Ljubljana)</source><rights>BY</rights><subject language_type_id="eng">Antineoplastic agents</subject><subject language_type_id="slv">Antineoplastiki</subject><subject language_type_id="eng">drug</subject><subject language_type_id="eng">Drug therapy</subject><subject language_type_id="eng">Neoplasms</subject><subject language_type_id="slv">Novotvorbe</subject><subject language_type_id="slv">rak (medicina)</subject><subject language_type_id="eng">therapy</subject><subject language_type_id="eng">tumor</subject><subject language_type_id="slv">zdravila</subject><subject language_type_id="slv">zdravljenje</subject><title>Nova zdravila za zdravljenje raka</title></Record>